| # | Drug | Count |
|---|---|---|
| 0 | BEVACIZUMAB | 197 |
| 1 | PEMBROLIZUMAB | 78 |
| 2 | OXALIPLATIN | 77 |
| 3 | PACLITAXEL | 77 |
| 4 | CARBOPLATIN | 75 |
| 5 | CISPLATIN | 74 |
| 6 | FLUOROURACIL | 71 |
| 7 | FLUOROURACIL CREAM, 0.5% | 71 |
| 8 | PACLITAXEL (AIBUMIN-BOUND) | 63 |
| 9 | CYCLOPHOSPHAMIDE | 52 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | STREPTOZOCIN | 10 | 0.0435 |
| 1 | FENTANYL TRANSDERMAL | 1 | 0.0303 |
| 2 | ATRASENTAN | 1 | 0.0099 |
| 3 | DIETHYLPROPION HYDROCHLORIDE | 1 | 0.0078 |
| 4 | PLATINUM | 2 | 0.0038 |
| 5 | DACTINOMYCIN | 8 | 0.0036 |
| 6 | CHORIONIC GONADOTROPIN | 2 | 0.0036 |
| 7 | INTERLEUKIN-10 | 1 | 0.0028 |
| 8 | MITOTANE | 5 | 0.0027 |
| 9 | FOSNETUPITANT AND PALONOSETRON | 3 | 0.0025 |
| # | Drug class | Count |
|---|---|---|
| 0 | Platinum-based Drug [EPC] | 210 |
| 1 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 197 |
| 2 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 169 |
| 3 | Kinase Inhibitor [EPC] | 134 |
| 4 | Alkylating Drug [EPC] | 126 |
| 5 | Nucleoside Metabolic Inhibitor [EPC] | 120 |
| 6 | Corticosteroid [EPC] | 106 |
| 7 | Microtubule Inhibitor [EPC] | 103 |
| 8 | Folate Analog Metabolic Inhibitor [EPC] | 57 |
| 9 | Nonsteroidal Anti-inflammatory Drug [EPC] | 56 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Actinomycin [EPC] | 8 | 0.0036 |
| 1 | Lymphocyte Growth Factor [EPC] | 3 | 0.0024 |
| 2 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 169 | 0.0017 |
| 3 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 197 | 0.0011 |
| 4 | Somatostatin Analog [EPC] | 7 | 0.0010 |
| 5 | Platinum-based Drug [EPC] | 210 | 0.0008 |
| 6 | Chemokine Receptor Type 4 Interaction [EPC] | 1 | 0.0007 |
| 7 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 6 | 0.0007 |
| 8 | Claudin 18.2-directed Cytolytic Antibody [EPC] | 1 | 0.0007 |
| 9 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 4 | 0.0006 |